FDA Approves Bristol-Myers Squibb Company’s Drug That Prevents Organ Rejection

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY - News) today announced that the U.S. Food & Drug Administration has approved NULOJIX (belatacept).

Please see accompanying Full Prescribing Information, including Boxed WARNINGS at www.NULOJIX.com or www.bms.com.

NULOJIX is a registered trademark of Bristol-Myers Squibb.